ACELYRIN (Nasdaq: SLRN) received unsolicited offer from Concentra Biosciences, LLC for $3.00 per share.

From GlobeNewswire: 2025-02-20 21:00:00

ACELYRIN, INC. (Nasdaq: SLRN) received an unsolicited offer from Concentra Biosciences, LLC to acquire all outstanding shares for $3.00 per share in cash, plus a contingent value right. ACELYRIN previously announced a merger with Alumis Inc. (Nasdaq: ALMS) expected to close in Q2 2025. The ACELYRIN Board of Directors will act in stockholders’ best interests; no action is required at this time. Guggenheim Securities, LLC is the financial advisor, with legal counsel provided by Fenwick & West LLP and Paul Hastings LLP. ACELYRIN focuses on developing transformative medicines, with the lead program lonigutamab targeting thyroid eye disease.

The proposed transaction faces risks such as potential failure to receive required approvals, impact on key personnel, and legal proceedings. Additional risk factors will be detailed in the registration statement and joint proxy statement/prospectus filed with the SEC. Alumis and ACELYRIN urge security holders to review these documents before making any decisions. No update on forward-looking statements is expected unless required by law. Alumis and ACELYRIN will provide information about the proposed transaction through the SEC. Directors and officers of both companies may participate in soliciting proxies for the transaction. This communication is not an offer to sell securities or solicit votes. Contact Tyler Marciniak for Investor Relations and Media at [email protected].



Read more at GlobeNewswire: ACELYRIN Confirms Receipt of Unsolicited Indication of